

1 **Title:** Myonuclear apoptosis underlies diaphragm atrophy in mechanically ventilated ICU
2 patients.

3 **Authors:** Wout J. Claassen¹, Marloes van den Berg^{1,3}, Zhong-Hua Shi¹, Rianne J. Baelde¹,
4 Sylvia Bogaards¹, Luuk Bonis¹, Heleen Hakkeling¹, Arezou Bamyani¹, Gerben J. Schaaf⁴,
5 Albertus Beishuizen⁵, Chris Dickhoff², Reinier A. Boon¹, Leo Heunks⁶, Tyler J. Kirby^{1,*}, Coen
6 A.C. Ottenheijm^{1,3,*}

7 **Affiliations:** Amsterdam UMC, location VUmc ¹Department of Physiology, ²Department of
8 Surgery, Amsterdam, the Netherlands ³University of Arizona, Department of Cellular and
9 Molecular Medicine, Tucson, AZ, USA ⁴Erasmus University Medical Center, Center for
10 Lysosomal and Metabolic Diseases, Rotterdam, the Netherlands, ⁵Medisch Spectrum
11 Twente, Intensive care Center, Enschede, the Netherlands. ⁶Radboudumc, Department of
12 Intensive Care Medicine, Nijmegen, the Netherlands

13 *** Correspondence.** Coen A.C. Ottenheijm (c.ottenheijm@amsterdamumc.nl) and Tyler J.
14 Kirby (t.kirby@amsterdamumc.nl)

15 **Author contributions:** WJC, CACO and TJK designed the study. WJC, ZHS and MvB, were
16 responsible for sample collection, WJC, ZHS, RRB, SB, LB, HH, ABa, GJS performed
17 experiments in the laboratory. ABe, CD, LH were responsible for patient recruitment. WJC,
18 LB, HH and ABa were responsible for data collection and management. WJC, LB, HH and
19 ABa performed statistical analysis and created figures. WJC drafted the manuscript. CACO,
20 TJK, LH, RAB, and WJC critically revised the manuscript. All authors read and approved the
21 manuscript.

22 **Funding:** Supported by NHLBI grant HL-121500 (C.A.C.O.); ZonMW Grant

23 **Word Count:** 4706

24

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **Abstract** (249 words)

27 **Rationale.** Mechanical ventilation plays an important role in critical illness-associated
28 diaphragm weakness. Weakness contributes to difficult weaning and is associated with
29 increased morbidity and mortality. Diaphragm weakness is caused by a combination of
30 atrophy and dysfunction of myofibers, which are large syncytial cells maintained by a
31 population of myonuclei. Each myonucleus provides gene transcripts to a finite fiber volume,
32 termed the myonuclear domain. Changes in myonuclear number in myofibers undergoing
33 atrophy has not been investigated in mechanically ventilated ICU patients. Myonuclear
34 number is a determinant of transcriptional capacity, and therefore critical for muscle
35 regeneration after atrophy.

36 **Objectives.** Our objective was to investigate if and how myonuclear number changes in the
37 diaphragm of mechanically ventilated ICU patients and whether changes are associated with
38 myofiber atrophy.

39 **Methods.** We used a combination of transcriptomics, immunohistochemistry, and confocal
40 microscopy to study myonuclear alterations in diaphragm and quadriceps biopsies from
41 mechanically ventilated ICU patients.

42 **Results.** Myonuclear number and myonuclear domain were reduced in patients with
43 diaphragm myofiber atrophy. Intrinsic apoptotic pathway activation was identified as a
44 mechanism underlying myonuclear removal in the diaphragm of mechanically ventilated ICU
45 patients. Total transcriptional activity in myofibers decreased with myonuclear loss.
46 Furthermore, muscle stem cell number was reduced in the patients with diaphragm atrophy.

47 **Conclusion.** We identified myonuclear loss due to intrinsic apoptotic pathway activation as a
48 potential mechanism underlying diaphragm atrophy in mechanically ventilated patients. This
49 provides novel insights in diaphragm weakness of ICU patients. Targeted therapies may limit
50 development of diaphragm weakness and improve weaning outcome.

51

52 **Introduction**

53 Weakness of the diaphragm is a well-known consequence of critical illness and mechanical
54 ventilation (MV) in patients admitted to the intensive care unit (ICU). It contributes to difficult
55 weaning, which is associated with increased morbidity, mortality, and healthcare costs (1).
56 Furthermore, it can lead to physical disability and long-term impairment in intensive care
57 survivors (2). Diaphragm weakness is caused by a combination of atrophy and dysfunction of
58 the remaining contractile material, leading to weakness of muscle cells (i.e., myofibers). In
59 recent years, several mechanisms underlying contractile dysfunction have been identified (3-
60 5), including changes in myosin conformation (6). The mechanisms underlying atrophy are
61 not well understood. Increased proteolysis, resulting in a reduction of contractile material,
62 may play a role (7, 8), but it is unclear whether other pathways contribute as well. Identifying
63 the pathways that are involved in diaphragm myofiber atrophy will have important
64 considerations for the development of therapies and for clinical practice, as diaphragm
65 atrophy is associated with prolonged mechanical ventilation, longer ICU length of stay and
66 increased risk of complications (9, 10).

67 Myofibers are large syncytial cells that are maintained by a population of post-mitotic
68 myonuclei. Each myonucleus provides gene transcripts to a finite fiber volume, termed the
69 myonuclear domain (11-14). During changes in muscle mass, myofibers' nuclear number
70 may change (15). In several pathological states resulting in myofiber atrophy, apoptosis
71 regulates myonuclear number (16). In the diaphragm of ventilated rodents and brain-dead
72 organ donors, myonuclear loss and upregulated apoptosis were identified to underlie
73 diaphragm atrophy, but these pathways have not yet been investigated in ventilated ICU
74 patients (17, 18). Furthermore, the brain-dead organ donors and rodents are very different
75 from typical ICU patients, from perspective of ventilator mode, but also systemic
76 inflammation and exposure to drugs; therefore, these models do not adequately reflect ICU
77 patients (17). It is critical to investigate whether apoptosis and myonuclear loss occur in
78 these patients as, during weaning, the diaphragm needs to regain mass and function for

79 which nuclear number and their transcriptional activity are important (19, 20). Furthermore,
80 loss of myonuclei may lead to longer-term functional impairment and weakness after hospital
81 discharge, with have important consequences for patients including the risk for ICU
82 readmission and persistent dyspnea (21). Finally, if myonuclear apoptosis plays a role in
83 critical illness-associated diaphragm weakness, inhibiting the underlying mechanism may be
84 a promising therapeutic venue (19, 20).

85 Thus, our objective was to study apoptotic pathways and myonuclear regulation in the
86 diaphragm of mechanically ventilated ICU patients. Hence, we performed next-generation
87 RNA-sequencing in diaphragm biopsies of MV ICU patients and immunofluorescence
88 labeling of biopsy cryosections to investigate whether myonuclei undergo apoptosis.
89 Furthermore, we studied myonuclear number and morphology in myofibers isolated from
90 diaphragm biopsies. Additionally, we obtained quadriceps biopsies of MV ICU patients to
91 investigate whether our findings were specific to the diaphragm. Some of the results of these
92 studies have been previously reported in conference abstracts and as a preprint (22, 23).

93 **Methods**

94 For further details on the applied methods, see the online supplement.

95 *Patients, diaphragm biopsies*

96 Diaphragm muscle biopsies were obtained from ICU patients receiving invasive mechanical
97 ventilation (*ICU patients, n = 24*) and patients undergoing elective lung surgery for early-
98 stage lung malignancy without critical illness (*Control patients, n = 10*). Exclusion criteria
99 were chronic obstructive pulmonary disease (\geq GOLD stage III), congestive heart failure,
100 neuromuscular diseases, chronic metabolic disorders, pulmonary hypertension, chronic use
101 of corticosteroids ($> 7.5\text{mg/day}$ for at least 3 months), and more than 10% weight loss within
102 the last 6 months. The exclusion criteria were similar for all experimental groups. Patients'
103 characteristics are presented in Table 1. The biopsy protocol was approved by the
104 institutional review board at Amsterdam UMC (location VUmc), the Netherlands. Patients
105 were recruited in Amsterdam UMC, the Netherlands Cancer Institute-Antoni van

106 Leeuwenhoek Hospital (both in Amsterdam, the Netherlands), and Medisch Spectrum
107 Twente (Enschede, the Netherlands). Written informed consent was obtained from the
108 patients or their legal representative.

109 *Patients, quadriceps biopsies*

110 Quadriceps biopsies of ICU patients ($n = 10$) were obtained in the context of a separate
111 study that has been filed in the Clinical Trial Register under #NCT03231540 and was
112 approved by the Medical Ethical Committee of VU Medical Center, Amsterdam, the
113 Netherlands. Informed consent was obtained from the patient or a legal representative.
114 Patients ≥ 18 years that had an expected ventilation duration of ≥ 72 hours, were expected to
115 tolerate enteral nutrition ≥ 72 hours, and had a Sequential Organ Failure Assessment (SOFA)
116 score ≥ 6 , were considered eligible for inclusion. Exclusion criteria were contra-indications to
117 enteral nutrition, short bowel syndrome, type C liver cirrhosis or acute liver failure,
118 dependency on renal replacement therapy, requiring another specific enteral nutrition
119 formula for medical reasons, BMI > 35 kg/m², extensive treatment limitations, disseminated
120 malignancy, hematological malignancy, primary neuromuscular pathology, chronic use of
121 corticosteroids for > 7 days before ICU admission or contra-indications for muscle biopsy
122 such as the need for continuous systemic anticoagulation, INR > 1.3 or thrombocytes $< 100 \times$
123 $10^3 / \text{mm}^3$.

124 *Single myofiber microscopy*

125 Single myofibers were manually isolated from the biopsies. Myonuclear number, myofiber
126 volume, myonuclear morphology, and RNA-polymerase-II Ser5 fluorescence were
127 determined using immunofluorescence labeling in combination with confocal microscopy.

128 *RNA-sequencing*

129 RNA was extracted using a commercially available kit and sequenced using a NextSeq500
130 (Illumina).

131 *Immunohistochemistry*

132 Serial cryosections were cut from the biopsies and stained to study myonuclear number,
133 myonuclear domain, markers for apoptosis, and satellite cell content.

134 *Statistical analysis*

135 Normality of the distribution of the studied variables was assessed visually on normal
136 probability plots. Log transformation was performed if necessary. To compare the difference
137 between ICU patients and control patients, student's t-test or Mann-Whitney-U was applied
138 for non-repeat measurements; and linear mixed model with patients as the random factor
139 was applied for measurements involving technical replicates in all human samples. For linear
140 mixed models, Greenhouse-Geisser correction was applied to adjust for potential lack of
141 sphericity. For the comparison of three groups or more, one-way analysis of variance
142 (ANOVA) or Kruskal-Wallis tests were performed with Tukey's or Dunn's post-hoc tests,
143 depending on the distribution of the data. We used a two-sided significance level of 5% for all
144 analyses. Unless otherwise noted, data are expressed as mean (\pm standard error), median
145 [interquartile range], or frequencies (percentage), as appropriate.

146

147

148 **Results**

149 Diaphragm biopsies were collected from 24 mechanically ventilated ICU patients who
150 underwent laparotomy or thoracotomy for a clinical indication. The biopsies were collected
151 from the left anterolateral part of the zone of apposition of the diaphragm. In Table 1 we
152 summarize the clinical parameters. The biopsies were compared to the biopsies of 10
153 patients who underwent elective thoracic surgery for a small, primary pulmonary nodule. The
154 groups were matched for age, body mass index, and sex (Table 1). Due to the limited size of
155 the biopsies, not every biopsy was used in every experiment. Table S1 details which biopsies
156 were used for each experiment.

157 *Transcriptomics reveals upregulation of apoptotic pathways in the diaphragm*

158 To investigate the mechanisms underlying diaphragm weakness and atrophy, we performed
159 next-generation RNA-sequencing of whole tissue samples cut from the biopsies. Table S2
160 shows the clinical characteristics of the patients included in this experiment. Principal
161 component analysis (PCA) revealed clear clustering in the control patients, while the ICU
162 group showed a more variable clustering pattern (Fig. 1A). We identified 2977 differentially
163 expressed genes (1741 upregulated in the ICU group and 1236 downregulated (Fig. 1B)
164 between control and ICU patients. A heatmap of the top 50 differentially expressed genes
165 was generated (Fig. 1C). Next, we performed Panther pathway enrichment analysis of
166 significant (FDR < 0.2, dashed line represents p -value of 0.05) differentially expressed genes
167 (Fig. 1D). Consistent with our hypothesis of increased apoptosis in ICU patients, the top
168 upregulated pathways in the ICU group were the p53, apoptosis, and integrin signaling
169 pathways. Thus, in mechanically ventilated ICU patients, the p53 and apoptosis pathways
170 are upregulated (Fig. 1E, S1A), providing a potential mechanism underlying weakness and
171 atrophy.

172 *Caspase-3-mediated apoptosis of myonuclei*

173 As bulk-tissue RNA-sequencing revealed marked upregulation of the apoptotic pathway, next
174 we performed analyses on muscle cross-sections to allow for the identification of different
175 cell types that may be undergoing apoptosis. We used multiple markers to distinguish
176 myonuclei from non-myonuclei (e.g. pericentreolar-material-1 (PCM1) (24) and
177 dystrophin/laminin immunolabeling), as previously it was suggested that much of the
178 apoptosis that occurs during muscle atrophy can be attributed to the non-myonuclear cell
179 pool (24). Tables S3 and S4 show the characteristics of the patients included in these
180 experiments. The percentage of myonuclei undergoing apoptosis was determined using
181 terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) of double-stranded
182 DNA breaks (Fig. 2A). Representative images of TUNEL labeling of a DNase-I treated
183 diaphragm section (positive control) are shown in Fig. S2. The mean TUNEL-index (number
184 of TUNEL-positive myonuclei divided by the total number of myonuclei) in the ICU group was
185 almost double that of the control group (Fig. 2B). There was no difference in TUNEL-index
186 for other cell types (Fig. S3A). Furthermore, we used an antibody for cleaved (i.e. activated)
187 caspase-3 to investigate the role of caspase-3 mediated nuclear apoptosis (Fig. 2C) (25).
188 The mean activated caspase-3 index (number of cleaved caspase-3-positive myonuclei
189 divided by the total number of myonuclei) was ~3-fold higher in the ICU group (Fig. 2D).
190 Caspase-3-index for other cell types was also higher in the ICU group (Fig. S3B).
191 Next, to investigate whether our findings are specific to the diaphragm, we obtained
192 quadriceps muscle biopsies ($n = 10$) and compared them to healthy controls ($n = 5$). Tables 2
193 and S5 show the clinical characteristics of these groups. Note that the duration of mechanical
194 ventilation and disease severity is similar to that of the groups from which diaphragm
195 biopsies were obtained. The percentage of myonuclei undergoing apoptosis was determined
196 using the same activated caspase-3 immunofluorescence protocol used for the diaphragm
197 biopsies (Fig. S4A). In the ICU group, the activated caspase-3 index of both myonuclei and
198 other cell types was almost double that of the control group, but still more than two-fold lower
199 than in the diaphragm (Fig. S4B, C, S5). The mean myofiber CSA was similar in the ICU and

200 control groups (Fig. S4D), suggesting that in the quadriceps of MV ICU patients, caspase-3
201 activation occurs before the onset of atrophy.

202 Thus, both our transcriptomic and immunofluorescence data support a mechanism where
203 caspase-3-mediated apoptosis is increased during critical illness-associated diaphragm
204 weakness and is increased in quadriceps muscle before the onset of atrophy.

205 *Decreased myonuclear number and myonuclear domain in atrophic diaphragm fibers*

206 To investigate whether the upregulation of apoptosis in myonuclei resulted in a reduced
207 myonuclear number, we counted myonuclei in 8-12 myofibers per biopsy that were randomly
208 selected and manually isolated. This method allows for a precise determination of
209 myonuclear number per myofiber volume. Myonuclear domain was determined by dividing
210 myofiber volume by myonuclear number. Immunofluorescent staining of myonuclear marker
211 PCM1 revealed that the proportion of PCM1 positive myonuclei within the isolated myofibers
212 ($n = 3$ control and $n = 3$ ICU, Table S6) was >98% in both groups, showing that the number
213 of non-myonuclei included in the preparations did not impact nuclear number (Fig. S6). Fast
214 and slow-twitch fibers were identified by immunoreactivity for fast-twitch myosin heavy chain
215 isoform and data were segregated according to fiber type.

216 Myofiber volume and myonuclear domain size were lower in the ICU group, but nuclear
217 number was not significantly lower (Fig. S7). We hypothesized that we did not observe a
218 difference in myonuclear number due to the presence of patients in the ICU group with a
219 myofiber volume similar to that of the controls. Therefore, to investigate whether myonuclear
220 number was reduced specifically in ICU patients with atrophy, we separated the ICU group
221 into two groups: one with atrophy (ICU A+) and one without atrophy (ICU A-). To this end,
222 we used myofiber CSA data derived from cryosections (mean size of ~450 myofibers). For
223 the ICU A-- group, the lower limit of the CSA was set at the median CSA of the control group
224 (CSA of $2500 \mu\text{m}^2$). To ensure minimal overlap between the groups, the upper limit of the

225 ICU A+ group was set at a CSA of 2000 μm^2 . Clinical characteristics of all groups are shown
226 in Table 1.

227 As expected, the volume of the isolated myofibers in the ICU A+ group was ~50% smaller
228 compared to the ICU A- and control groups, and this difference was similar for both fiber
229 types (Fig. 3C). In the ICU A+ group, myonuclear number was reduced by about 35% in both
230 fast and slow myofibers when compared to the ICU A- and the control group (Fig. 3D). To
231 verify whether our findings in single myofibers were representative of a larger sample, we
232 validated these findings by analyzing the number of myonuclei per myofiber in diaphragm
233 muscle cross-sections with an average size of 498 myofibers per section. Myonuclei were
234 identified using PCM1 labeling in combination with localization within the dystrophin barrier
235 (note that we did not stain for myofiber type). In muscle cross-sections, average myonuclear
236 counts per fiber were reduced by about 39% in the ICU A+ group compared to the control
237 group (Fig. S8B), which was consistent with the results from the isolated myofibers (Fig. 3D).
238 Next, we counted the myonuclei present in the quadriceps cross-sections, and found that
239 there was no difference in the number of myonuclei per myofiber between the control and
240 ICU patients (Fig. S8C). In the isolated myofibers, myonuclear domain size was smaller in
241 the ICU A+ group when compared to the control group, but not when compared to the ICU
242 A- group (Fig. 3E). When we examined the relationship between myofiber CSA and
243 myonuclear number, we found a comparable positive correlation in all three groups (Fig.
244 S9A). Myonuclear domain size and myofiber CSA showed a similar positive correlation, but
245 the elevation of the regression line in the ICU A+ group was significantly lower, indicating
246 smaller myonuclear domains for the same CSA. The slope of the regression line of the fibers
247 isolated from the biopsies of ICU A- patients had a significantly steeper relationship between
248 myonuclear domain and cross-sectional area compared to the ICU A- group (Fig. S9B). In
249 conclusion, myonuclear number is reduced in myofibers in the atrophic diaphragm of
250 mechanically ventilated ICU patients, and myonuclear domain is smaller, indicating relatively

251 more atrophy than myonuclear loss. Furthermore, the reduction in myonuclear number was
252 absent in the diaphragm of similar ICU patients without established atrophy.

253 Thus, atrophic diaphragm myofibers have a reduced number of myonuclei. In the diaphragm,
254 loss of myonuclei appears to commence before the onset of atrophy, and before changes in
255 myonuclear number in limb muscle. This may have profound implications for weaning and
256 recovery after ICU and hospital discharge, as it has been proposed that myofibers depend on
257 their myonuclear content for recovery after atrophy (26).

258 *Changes in myonuclear morphology*

259 In addition to myonuclear number, myonuclear size is known to scale with myofiber size (27).
260 Based on the changes we observed in myonuclear number, we sought to study changes in
261 myonuclear morphology by segmenting every 3D-rendered nucleus present within the Z-
262 stacks of the myofibers (Fig. 4A). Myonuclear volume was reduced in ICU A+ patients (Fig.
263 4B), and the cumulative fluorescence intensity of the nuclear lamina (lamin A/C) within each
264 nucleus was increased (Fig. 4C). An increased total fluorescent intensity of the nuclear
265 lamina may indicate increased nuclear wrinkling or increased thickness of the nuclear
266 lamina. To further study this, we determined the wrinkling index of each nucleus by
267 measuring the standard deviation of the fluorescence intensity within each segmented
268 nucleus in maximum intensity Z-projections of the Z-stacks (Fig. 4D) (28). Nuclear wrinkling
269 was increased in the ICU A+ and A- groups, when compared to the control group (Fig. 4E).
270 Mean ellipticity or sphericity, two shape descriptors of sphere-like objects, were not different
271 between the groups (Fig. S10 A-B). Thus, nuclear volume was lower in the ICU A+ group
272 and myonuclear wrinkling was increased in in both ICU A+ and ICU A- patients.

273 *Diminished transcriptional activity of myofibers in the atrophic diaphragm of mechanically* 274 *ventilated ICU patients*

275 Myonuclear number has been shown to influence myonuclear transcription, with transcription
276 levels increasing with decreasing nuclear number (29, 30). Thus, we aimed to determine
277 whether changes in myonuclear number and morphology resulted in changes in myonuclear

278 transcription in ICU patients. We hypothesized that diminished transcriptional activity
279 contributes to atrophy in ICU patients. Furthermore, transcriptional activity may be
280 downscaled with the reduced myonuclear domain size in ICU A+ patients, because the
281 cellular volume to regulate is smaller. The transcriptional activity of each nucleus was
282 determined by measuring the fluorescent intensity of phosphorylated Serine 5 on RNA-
283 polymerase-2. This phosphorylation occurs shortly after the initiation of transcription, before
284 the capping of the mRNA (31, 32) (Fig. 5A), and strongly correlates with transcriptional
285 activity (33, 34). We measured the intensity of the immunofluorescence of activated RNA-
286 polymerase-2 within each nucleus (Fig. 5B) from ten randomly selected myofibers of 5
287 patients from the ICU group and 5 controls (Table S7). Total transcriptional activity per fiber
288 was calculated by summation of the fluorescence intensity of RNA-pol-II Ser5 labeling within
289 each nucleus present in the myofiber and was on average almost two-fold lower in the ICU
290 A+ group compared to the control group (Fig. 5C). This was explained by the lower
291 myonuclear number in ICU myofibers, because the fluorescence intensity of RNA-Pol-II Ser5
292 per nucleus did not differ between the groups (Fig. 5D). After normalization to fiber volume,
293 the difference in transcriptional activity per fiber was absent (Fig. 5E). Thus, based on these
294 findings, insufficient transcriptional activity of individual nuclei is unlikely to contribute to
295 atrophy, whereas the reduced myonuclear number in the ICU group with atrophy may reduce
296 total transcriptional activity per myofiber.

297 *Decreased muscle stem cell number in the diaphragm of ICU patients*

298 After muscles undergo atrophy that is accompanied by loss of myonuclei (Fig. 3) and
299 transcriptional capacity (Fig. 5), myonuclear number could be restored by the contribution of
300 satellite cells, the resident stem cells present adjacent to myofibers that contribute to
301 myofiber homeostasis (35). Interestingly, muscle stem cell activity is particularly high in the
302 diaphragm (36, 37). Thus, we aimed to investigate whether the muscle stem cell population
303 in the atrophic diaphragm is affected, as this could further impair muscle recovery after
304 atrophy. First, in our RNA-seq data set, we found a lower relative expression of *PAX7*, a

305 transcript uniformly expressed in muscle stem cells (38), in both ICU groups compared to the
306 control group (Fig. S1B). Next, immunofluorescent labeling of *PAX7* was performed to
307 determine the number of muscle stem cells in diaphragm cross-sections (Fig. 6A). Patient
308 characteristics of the groups used in these experiments are shown in Table S8. In ICU
309 patients with atrophy, satellite cell content was reduced when normalized for either the
310 number of myofibers present within the section (Fig. 6B) or when normalized for total section
311 area (Fig. 6C). In conclusion, satellite cell content is reduced in the atrophic diaphragm of
312 mechanically ventilated patients, potentially impeding the restoration of myonuclear number
313 during recovery.

314

315 **Discussion**

316 In this study, transcriptome profiling identified apoptotic pathway activation as a potential
317 mechanism underlying critical illness-associated diaphragm weakness. Increased apoptosis
318 of myonuclei was confirmed by using staining of cross-sections. Furthermore, this is the first
319 study to reveal reduced myonuclear number in mechanically ventilated ICU patients. We
320 show that myonuclear loss is associated with a reduction in transcriptional activity within
321 myofibers. Having lost a significant number of myonuclei may put patients at a disadvantage
322 during ventilator weaning and also may have long-term consequences after ICU discharge,
323 because muscle growth and recovery is associated with myonuclear number (19, 20).
324 Reduced myonuclear number in atrophic myofibers implies that recovery of strength requires
325 the addition of new myonuclei from satellite cells, instead of solely increasing protein
326 synthesis to recover lost contractile material (Fig. 7) (39). Importantly, we discovered a
327 reduced number of satellite cells in the diaphragm of ICU patients, possibly leading to further
328 impairment of recovery after atrophy. Discovery of this underlying mechanism may pave the
329 way for new treatments to prevent diaphragm atrophy.

330

331 *Myonuclear apoptosis in the diaphragm*

332 The fate of myonuclei in muscles undergoing atrophy is subject to debate (40-42). The
333 changes in myonuclear number and domain during atrophy likely depend on the type of
334 atrophic stimulus (11, 43). Our observation that mechanical ventilation may induce caspase-
335 3-mediated apoptosis of myonuclei is in accordance with the findings of a study investigating
336 diaphragm atrophy in mechanically ventilated rats (6 and 12 h) (44). The authors reported no
337 changes in myonuclear domain size, indicating atrophy that was proportional to myonuclear
338 loss. In our study, the myonuclear domain was significantly smaller in the ICU group with
339 established atrophy compared to controls, implying more or faster atrophy than myonuclear
340 loss. There are several potential explanations for this discrepancy. First, we used 3D
341 rendering of Z-stacks of confocal images to measure myonuclear domain volume within
342 single myofibers, a more sensitive method compared to the myonuclear domain surface area
343 (2D) measurements done on muscle cross-sections in the rodent study (15). Second, the
344 patients in this study had a median ventilation duration of more than 60 hours, much longer
345 than the 12 hours in the rodent study. In larger clinical studies, duration of ventilation was
346 associated with the degree of diaphragm atrophy (45). The longer time on mechanical
347 ventilation in our study may explain the reduction in myonuclear domain size, with atrophy
348 exceeding myonuclear loss. Finally, unlike critically ill patients, the mechanically ventilated
349 rodents were healthy. Common conditions in the ICU such as systemic inflammation and
350 increased metabolic demand may independently cause muscle wasting, further accelerating
351 atrophy (46). The pathophysiology of diaphragm atrophy has also been evaluated in
352 mechanically ventilated brain-dead organ donors (7). Oxidative stress and mitochondrial
353 dysfunction were suggested to activate the intrinsic pathway leading to caspase-3 activation
354 and apoptosis (18). In diaphragm biopsies of mechanically ventilated ICU patients, a redox
355 imbalance was proposed to underlie diaphragm atrophy in the absence of mitochondrial
356 dysfunction or oxidative stress. This discrepancy may be due to the difference in clinical
357 features between brain-dead organ donors and mechanically ventilated ICU patients.

358 In quadriceps muscle biopsies of ICU patients, we showed increased caspase-3 activity,
359 albeit at a lower level than in the diaphragm, indicating caspase-3 activation before the onset
360 of muscle atrophy and loss of myonuclei, independent of MV. Indeed, in the quadriceps of
361 MV ICU patients, atrophy has been shown to occur later (7 days) after ICU admission (47).

362 In this study, we report a transcriptomic profile of the diaphragm of mechanically ventilated
363 ICU patients. Main findings include the upregulation of 20 genes associated with the p53
364 pathway, as well as the upregulation of 16 genes associated with apoptosis. Because p53 is
365 subject to redox regulation, a redox imbalance may activate the pathway (48). The p53
366 pathway was upregulated in various animal models of muscle atrophy. In mouse soleus
367 muscle, after 48 of hind limb suspension, the p53 pathway was upregulated and the
368 apoptotic index was increased (49). In a recent study in mechanically ventilated rabbits, the
369 p53 pathway was upregulated and was hypothesized to contribute to diaphragm weakness
370 via increased senescence (50). Interestingly, the p53 and apoptosis pathways were not
371 upregulated in a transcriptomics study of the atrophic diaphragm of controlled mechanically
372 ventilated rats (51). This demonstrates the disparity between animal models and clinical
373 reality, further underlining the need to study pathophysiology in samples from patients.

374 Finally, 19 genes associated with the integrin pathway were upregulated in the diaphragm of
375 ICU patients. This pathway is associated with the transmission of forces from the
376 extracellular matrix to actin and has been shown to be upregulated after eccentric
377 (lengthening) contractions (52). Eccentric contractions of the diaphragm may occur during
378 ineffective efforts, premature cycling or reverse triggering, a ventilator asynchrony that has
379 been shown to contribute to diaphragm dysfunction and myofiber injury in MV pigs with high
380 respiratory effort (53, 54). Therefore, our data support a role for eccentric contractions in the
381 pathophysiology of critical illness associated diaphragm weakness.

382 *Decreased number of satellite cells in the mechanically ventilated diaphragm*

383 Our results show that the number of *PAX7* expressing cells is reduced in the diaphragm of
384 mechanically ventilated ICU patients. This may be a direct effect of increased apoptosis, but

385 we did not perform a separate experiment to quantify apoptotic satellite cells. Only a small
386 fraction of cells in our cross-sections expressed *PAX7* (0.05-0.1%) Therefore, it is technically
387 challenging to capture apoptotic satellite cells, especially because of diaphragm biopsy size
388 limitations. Whether satellite cells are required for muscle regeneration depends on the type
389 of atrophy, and on whether myonuclei are lost during atrophy (35, 55, 56). Nevertheless,
390 lineage tracing studies demonstrated that satellite cell activity is particularly high in the
391 diaphragm under non-diseased conditions (36, 37). In addition, there are interstitial stem
392 cells that can contribute to myofibers that do not express *PAX7* (57-60). Future studies
393 should determine the prevalence of non-satellite cell myogenic progenitors in the diaphragm
394 of humans, and whether these cells are a significant source of myonuclei during diaphragm
395 muscle homeostasis. Satellite cell content was reduced in the quadriceps of mechanically
396 ventilated patients with sustained atrophy after 6 months, suggesting a crucial role for
397 satellite cells during muscle regeneration in ICU patients (54). However, the exact role of
398 satellite cells during recovery after diaphragm atrophy warrants further investigation.

399 Disturbed sarcomeric integrity is accepted as one of the mechanisms contributing to critical
400 illness-associated diaphragm weakness (8). In non-diseased conditions, muscle can repair
401 its sarcomeres, as damage occurs during both exercise and normal use. After sarcomeres
402 are damaged, nuclear movement to a site of injury is required for repair (61, 62). During this
403 process, myonuclei migrate toward damaged muscle sections to supply mRNA for
404 sarcomeric proteins, allowing the reassembly of the contractile machinery (61). This
405 mechanism may be disturbed in critical illness-associated diaphragm weakness because
406 sarcomeric damage and reduced myonuclear number are present simultaneously.

407 *Clinical implications*

408 The identification of intrinsic apoptotic pathway activation as a mechanism underlying
409 diaphragm atrophy in MV ICU patients may open therapeutic venues to limit diaphragm
410 weakness and weaning failure. The intrinsic apoptotic pathway plays a central role in many
411 pathologies (63). Therefore, many inhibitors targeting the different components of this

412 pathway have been developed (64). Especially caspase-3 inhibition has been investigated
413 extensively, and was shown to prevent diaphragm atrophy in mechanically ventilated rodents
414 (44, 65). To date, none have progressed beyond pre-clinical studies, probably due to
415 functions of caspase-3 outside of the intrinsic apoptotic pathway (65). However, there are
416 other strategies to limit apoptosis, such as limiting redox imbalance or inhibiting other
417 constituents of the intrinsic apoptotic pathway, such as BAX or BAK (64, 66). Additionally,
418 increasing the generation of new myonuclei by stimulating satellite cell activation may be a
419 strategy to help diaphragm recovery after atrophy and speed up the weaning process.
420 Signaling pathway and immune modulators and various growth factors have been shown to
421 augment satellite cell activation (67). More preclinical research is necessary to further
422 explore these targets. Even though our data does not suggest that apoptotic pathway
423 activation is limited to the diaphragm, we only observed myonuclear loss in the presence of
424 myofiber atrophy, suggesting an important role for strategies to prevent atrophy such as
425 diaphragm protective mechanical ventilation or diaphragm pacing (68, 69).

426 *Limitations*

427 The population of ICU patients included in this is highly heterogeneous, with varying medical
428 histories, reasons for admission, duration of mechanical ventilation and underlying
429 pathophysiology. Therefore, it is not feasible to search for clinical predictors associated with
430 myonuclear apoptosis or myofiber atrophy with our sample size. Nevertheless, this diverse
431 group of patients does adequately reflect the general ICU population. Due to the
432 invasiveness of taking diaphragm biopsies, the controls in this study are patients undergoing
433 surgery for a pulmonary nodule. We cannot rule out an effect of the clinical status of the
434 controls on the diaphragm, even though the in-and-exclusion criteria should minimize this.
435 Finally, due to biopsy size limitations, not all experiments were performed on all biopsies.

436 *Conclusion*

437 In mechanically ventilated patients in the ICU, myonuclear apoptosis is a pathophysiological
438 mechanism underlying critical illness-associated diaphragm atrophy. Using a combination of
439 advanced microscopy and molecular biology techniques, we identified p53 activation as the
440 underlying pathway in ICU patients. Myonuclear loss in combination with a reduction of the
441 satellite cell population may compromise recovery of the diaphragm, thereby contributing to
442 weaning failure.

443 **Funding:** Supported by NHLBI grant HL-121500 (C.A.C.O.); ZonMV Grant 09120011910004
444 (C.A.C.O; L.H.)

445

446 **References**

- 447 1. Dres M, Demoule A. Diaphragm dysfunction during weaning from mechanical
448 ventilation: an underestimated phenomenon with clinical implications. *Crit Care*.
449 2018;22(1):73.
- 450 2. Esteban A, Anzueto A, Frutos F, Alia I, Brochard L, Stewart TE, et al. Characteristics
451 and outcomes in adult patients receiving mechanical ventilation: a 28-day international study.
452 *JAMA*. 2002;287(3):345-55.
- 453 3. Penuelas O, Keough E, Lopez-Rodriguez L, Carriedo D, Goncalves G, Barreiro E,
454 Lorente JA. Ventilator-induced diaphragm dysfunction: translational mechanisms lead to
455 therapeutical alternatives in the critically ill. *Intensive Care Med Exp*. 2019;7(Suppl 1):48.
- 456 4. Zhang J, Feng J, Jia J, Wang X, Zhou J, Liu L. Research progress on the
457 pathogenesis and treatment of ventilator-induced diaphragm dysfunction. *Heliyon*.
458 2023;9(11):e22317.
- 459 5. Lindqvist J, van den Berg M, van der Pijl R, Hooijman PE, Beishuizen A, Elshof J, et
460 al. Positive End-Expiratory Pressure Ventilation Induces Longitudinal Atrophy in Diaphragm
461 Fibers. *Am J Respir Crit Care Med*. 2018;198(4):472-85.
- 462 6. van den Berg M, Shi Z, Claassen WJ, Hooijman P, Lewis CTA, Andersen JL, et al.
463 Super-relaxed myosins contribute to respiratory muscle hibernation in mechanically
464 ventilated patients. *Sci Transl Med*. 2024;16(758):eadg3894.
- 465 7. Levine S, Nguyen T, Taylor N, Friscia ME, Budak MT, Rothenberg P, et al. Rapid
466 disuse atrophy of diaphragm fibers in mechanically ventilated humans. *N Engl J Med*.
467 2008;358(13):1327-35.
- 468 8. Hooijman PE, Beishuizen A, Witt CC, de Waard MC, Girbes AR, Spoelstra-de Man
469 AM, et al. Diaphragm muscle fiber weakness and ubiquitin-proteasome activation in critically
470 ill patients. *Am J Respir Crit Care Med*. 2015;191(10):1126-38.
- 471 9. Poddighe D, Van Hollebeke M, Choudhary YQ, Campos DR, Schaeffer MR, Verbakel
472 JY, et al. Accuracy of respiratory muscle assessments to predict weaning outcomes: a
473 systematic review and comparative meta-analysis. *Crit Care*. 2024;28(1):70.
- 474 10. Goligher EC, Dres M, Fan E, Rubenfeld GD, Scales DC, Herridge MS, et al.
475 Mechanical Ventilation-induced Diaphragm Atrophy Strongly Impacts Clinical Outcomes. *Am*
476 *J Respir Crit Care Med*. 2018;197(2):204-13.
- 477 11. Verheul AJ, Mantilla CB, Zhan WZ, Bernal M, Dekhuijzen PN, Sieck GC. Influence of
478 corticosteroids on myonuclear domain size in the rat diaphragm muscle. *J Appl Physiol*
479 (1985). 2004;97(5):1715-22.

- 480 12. Hansson KA, Eftestol E, Bruusgaard JC, Juvkam I, Cramer AW, Malthe-Sorensen A,
481 et al. Myonuclear content regulates cell size with similar scaling properties in mice and
482 humans. *Nat Commun.* 2020;11(1):6288.
- 483 13. Bagley JR, Denes LT, McCarthy JJ, Wang ET, Murach KA. The myonuclear domain
484 in adult skeletal muscle fibres: past, present and future. *J Physiol.* 2023;601(4):723-41.
- 485 14. Hansson KA, Eftestol E. Scaling of nuclear numbers and their spatial arrangement in
486 skeletal muscle cell size regulation. *Mol Biol Cell.* 2023;34(8).
- 487 15. Snijders T, Aussieker T, Holwerda A, Parise G, van Loon LJC, Verdijk LB. The
488 concept of skeletal muscle memory: Evidence from animal and human studies. *Acta Physiol*
489 *(Oxf).* 2020;229(3):e13465.
- 490 16. Rahman FA, Quadriatero J. Mitochondrial Apoptotic Signaling Involvement in
491 Remodeling During Myogenesis and Skeletal Muscle Atrophy. *Semin Cell Dev Biol.*
492 2023;143:66-74.
- 493 17. van den Berg M, Hooijman PE, Beishuizen A, de Waard MC, Paul MA, Hartemink KJ,
494 et al. Diaphragm Atrophy and Weakness in the Absence of Mitochondrial Dysfunction in the
495 Critically Ill. *Am J Respir Crit Care Med.* 2017;196(12):1544-58.
- 496 18. Tang H, Lee M, Budak MT, Pietras N, Hittinger S, Vu M, et al. Intrinsic apoptosis in
497 mechanically ventilated human diaphragm: linkage to a novel Fos/FoxO1/Stat3-Bim axis.
498 *FASEB J.* 2011;25(9):2921-36.
- 499 19. Blocquiaux S, Gorski T, Van Roie E, Ramaekers M, Van Thienen R, Nielsens H, et al.
500 The effect of resistance training, detraining and retraining on muscle strength and power,
501 myofibre size, satellite cells and myonuclei in older men. *Exp Gerontol.* 2020;133:110860.
- 502 20. Petrella JK, Kim JS, Mayhew DL, Cross JM, Bamman MM. Potent myofiber
503 hypertrophy during resistance training in humans is associated with satellite cell-mediated
504 myonuclear addition: a cluster analysis. *J Appl Physiol (1985).* 2008;104(6):1736-42.
- 505 21. Demoule A, Decavele M, Antonelli M, Camporota L, Abroug F, Adler D, et al.
506 Dyspnoea in acutely ill mechanically ventilated adult patients: an ERS/ESICM statement. *Eur*
507 *Respir J.* 2024;63(2).
- 508 22. Claassen WJ, van der Berg M, Baelde RR, Bogaards S, Bonis L, Hakkeling H, et al.
509 Myonuclear apoptosis underlies diaphragm atrophy in mechanically ventilated ICU patients.
510 *medRxiv.* 2024:2024.07.23.24310792.
- 511 23. Claassen WJ, Kirby TJ, Heunks LM, Ottenheijm CA. ICU-acquired diaphragm
512 weakness: the role of the myonucleus. *Intensive Care Med Exp.* 2022(10 (suppl 2)):257-8.
- 513 24. Winje IM, Bengtson M, Eftestol E, Juvkam I, Bruusgaard JC, Gundersen K. Specific
514 labelling of myonuclei by an antibody against pericentriolar material 1 on skeletal muscle
515 tissue sections. *Acta Physiol (Oxf).* 2018;223(4):e13034.
- 516 25. Fry CS, Porter C, Sidossis LS, Nieten C, Reidy PT, Hundeshagen G, et al. Satellite
517 cell activation and apoptosis in skeletal muscle from severely burned children. *J Physiol.*
518 2016;594(18):5223-36.
- 519 26. Bruusgaard JC, Johansen IB, Egner IM, Rana ZA, Gundersen K. Myonuclei acquired
520 by overload exercise precede hypertrophy and are not lost on detraining. *Proc Natl Acad Sci*
521 *U S A.* 2010;107(34):15111-6.
- 522 27. Windner SE, Manhart A, Brown A, Mogilner A, Baylies MK. Nuclear Scaling Is
523 Coordinated among Individual Nuclei in Multinucleated Muscle Fibers. *Dev Cell.*
524 2019;49(1):48-62 e3.
- 525 28. Cosgrove BD, Loebel C, Driscoll TP, Tsinman TK, Dai EN, Heo SJ, et al. Nuclear
526 envelope wrinkling predicts mesenchymal progenitor cell mechano-response in 2D and 3D
527 microenvironments. *Biomaterials.* 2021;270:120662.
- 528 29. Cramer AAW, Prasad V, Eftestol E, Song T, Hansson KA, Dugdale HF, et al. Nuclear
529 numbers in syncytial muscle fibers promote size but limit the development of larger
530 myonuclear domains. *Nat Commun.* 2020;11(1):6287.
- 531 30. Kirby TJ, Patel RM, McClintock TS, Dupont-Versteegden EE, Peterson CA, McCarthy
532 JJ. Myonuclear transcription is responsive to mechanical load and DNA content but
533 uncoupled from cell size during hypertrophy. *Mol Biol Cell.* 2016;27(5):788-98.

- 534 31. Komarnitsky P, Cho EJ, Buratowski S. Different phosphorylated forms of RNA
535 polymerase II and associated mRNA processing factors during transcription. *Genes Dev.*
536 2000;14(19):2452-60.
- 537 32. Cho EJ, Takagi T, Moore CR, Buratowski S. mRNA capping enzyme is recruited to
538 the transcription complex by phosphorylation of the RNA polymerase II carboxy-terminal
539 domain. *Genes Dev.* 1997;11(24):3319-26.
- 540 33. Jeronimo C, Bataille AR, Robert F. The writers, readers, and functions of the RNA
541 polymerase II C-terminal domain code. *Chem Rev.* 2013;113(11):8491-522.
- 542 34. Bataille AR, Jeronimo C, Jacques PE, Laramée L, Fortin ME, Forest A, et al. A
543 universal RNA polymerase II CTD cycle is orchestrated by complex interplays between
544 kinase, phosphatase, and isomerase enzymes along genes. *Mol Cell.* 2012;45(2):158-70.
- 545 35. Sambasivan R, Yao R, Kissenpfennig A, Van Wittenberghe L, Paldi A, Gayraud-Morel
546 B, et al. Pax7-expressing satellite cells are indispensable for adult skeletal muscle
547 regeneration. *Development.* 2011;138(17):3647-56.
- 548 36. Pawlikowski B, Pulliam C, Betta ND, Kardon G, Olwin BB. Pervasive satellite cell
549 contribution to uninjured adult muscle fibers. *Skelet Muscle.* 2015;5:42.
- 550 37. Keefe AC, Lawson JA, Flygare SD, Fox ZD, Colasanto MP, Mathew SJ, et al. Muscle
551 stem cells contribute to myofibres in sedentary adult mice. *Nat Commun.* 2015;6:7087.
- 552 38. von Maltzahn J, Jones AE, Parks RJ, Rudnicki MA. Pax7 is critical for the normal
553 function of satellite cells in adult skeletal muscle. *Proc Natl Acad Sci U S A.*
554 2013;110(41):16474-9.
- 555 39. Bruusgaard JC, Gundersen K. In vivo time-lapse microscopy reveals no loss of
556 murine myonuclei during weeks of muscle atrophy. *J Clin Invest.* 2008;118(4):1450-7.
- 557 40. Kirby TJ, Dupont-Versteegden EE. Cross Talk rebuttal: Kirby and Dupont-
558 Versteegden. *J Physiol.* 2022;600(9):2085-6.
- 559 41. Kirby TJ, Dupont-Versteegden EE. Cross Talk proposal: Myonuclei are lost with
560 ageing and atrophy. *J Physiol.* 2022;600(9):2077-80.
- 561 42. Schwartz LM, Gundersen K. Cross Talk opposing view: Myonuclei do not undergo
562 apoptosis during skeletal muscle atrophy. *J Physiol.* 2022;600(9):2081-4.
- 563 43. Aravamudan B, Mantilla CB, Zhan WZ, Sieck GC. Denervation effects on myonuclear
564 domain size of rat diaphragm fibers. *J Appl Physiol (1985).* 2006;100(5):1617-22.
- 565 44. McClung JM, Kavazis AN, DeRuisseau KC, Falk DJ, Deering MA, Lee Y, et al.
566 Caspase-3 regulation of diaphragm myonuclear domain during mechanical ventilation-
567 induced atrophy. *Am J Respir Crit Care Med.* 2007;175(2):150-9.
- 568 45. Schepens T, Verbrugge W, Dams K, Corthouts B, Parizel PM, Jorens PG. The
569 course of diaphragm atrophy in ventilated patients assessed with ultrasound: a longitudinal
570 cohort study. *Crit Care.* 2015;19:422.
- 571 46. Petrof BJ. Diaphragm Weakness in the Critically Ill: Basic Mechanisms Reveal
572 Therapeutic Opportunities. *Chest.* 2018;154(6):1395-403.
- 573 47. Puthuchery ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, et al. Acute
574 skeletal muscle wasting in critical illness. *JAMA.* 2013;310(15):1591-600.
- 575 48. Eriksson SE, Ceder S, Bykov VJN, Wiman KG. p53 as a hub in cellular redox
576 regulation and therapeutic target in cancer. *J Mol Cell Biol.* 2019;11(4):330-41.
- 577 49. Ferreira R, Neuparth MJ, Vitorino R, Appell HJ, Amado F, Duarte JA. Evidences of
578 apoptosis during the early phases of soleus muscle atrophy in hindlimb suspended mice.
579 *Physiol Res.* 2008;57(4):601-11.
- 580 50. Shen W, Jiang Y, Xu Y, Qian X, Jia J, Ding Y, et al. Cellular senescence contributes
581 to mechanical ventilation-induced diaphragm dysfunction by upregulating p53 signalling
582 pathways. *BMC Pulm Med.* 2023;23(1):509.
- 583 51. Liu R, Li G, Ma H, Zhou X, Wang P, Zhao Y. Transcriptome profiling of the diaphragm
584 in a controlled mechanical ventilation model reveals key genes involved in ventilator-induced
585 diaphragmatic dysfunction. *BMC Genomics.* 2021;22(1):472.
- 586 52. Boppart MD, Mahmassani ZS. Integrin signaling: linking mechanical stimulation to
587 skeletal muscle hypertrophy. *Am J Physiol Cell Physiol.* 2019;317(4):C629-C41.

- 588 53. Garcia-Valdes P, Fernandez T, Jalil Y, Penailillo L, Damiani LF. Eccentric
589 Contractions of the Diaphragm During Mechanical Ventilation. *Respir Care*.
590 2023;68(12):1757-62.
- 591 54. Damiani LF, Engelberts D, Bastia L, Osada K, Katira BH, Otulakowski G, et al. Impact
592 of Reverse Triggering Dyssynchrony during Lung-Protective Ventilation on Diaphragm
593 Function: An Experimental Model. *Am J Respir Crit Care Med*. 2022;205(6):663-73.
- 594 55. Jackson JR, Mula J, Kirby TJ, Fry CS, Lee JD, Ubele MF, et al. Satellite cell depletion
595 does not inhibit adult skeletal muscle regrowth following unloading-induced atrophy. *Am J*
596 *Physiol Cell Physiol*. 2012;303(8):C854-61.
- 597 56. Lepper C, Partridge TA, Fan CM. An absolute requirement for Pax7-positive satellite
598 cells in acute injury-induced skeletal muscle regeneration. *Development*. 2011;138(17):3639-
599 46.
- 600 57. Gaulton N, Wakelin G, Young LV, Wotherspoon S, Kamal M, Parise G, et al. Twist2-
601 expressing cells reside in human skeletal muscle and are responsive to aging and resistance
602 exercise training. *FASEB J*. 2022;36(12):e22642.
- 603 58. Flynn CGK, Ginkel PRV, Hubert KA, Guo Q, Hrycaj SM, McDermott AE, et al. Hox11-
604 expressing interstitial cells contribute to adult skeletal muscle at homeostasis. *Development*.
605 2023;150(4).
- 606 59. Murach KA, Confides AL, Ho A, Jackson JR, Ghazala LS, Peterson CA, Dupont-
607 Versteegden EE. Depletion of Pax7+ satellite cells does not affect diaphragm adaptations to
608 running in young or aged mice. *J Physiol*. 2017;595(19):6299-311.
- 609 60. Liu N, Garry GA, Li S, Bezprozvannaya S, Sanchez-Ortiz E, Chen B, et al. A Twist2-
610 dependent progenitor cell contributes to adult skeletal muscle. *Nat Cell Biol*. 2017;19(3):202-
611 13.
- 612 61. Roman W, Pinheiro H, Pimentel MR, Segales J, Oliveira LM, Garcia-Dominguez E, et
613 al. Muscle repair after physiological damage relies on nuclear migration for cellular
614 reconstruction. *Science*. 2021;374(6565):355-9.
- 615 62. Roman W, Munoz-Canoves P. Muscle is a stage, and cells and factors are merely
616 players. *Trends Cell Biol*. 2022;32(10):835-40.
- 617 63. Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, et al. Apoptotic
618 cell death in disease-Current understanding of the NCCD 2023. *Cell Death Differ*.
619 2023;30(5):1097-154.
- 620 64. Li K, van Delft MF, Dewson G. Too much death can kill you: inhibiting intrinsic
621 apoptosis to treat disease. *EMBO J*. 2021;40(14):e107341.
- 622 65. Dhani S, Zhao Y, Zhivotovsky B. A long way to go: caspase inhibitors in clinical use.
623 *Cell Death Dis*. 2021;12(10):949.
- 624 66. Powers SK, Hudson MB, Nelson WB, Talbert EE, Min K, Szeto HH, et al.
625 Mitochondria-targeted antioxidants protect against mechanical ventilation-induced diaphragm
626 weakness. *Crit Care Med*. 2011;39(7):1749-59.
- 627 67. Schaaf GJ, Canibano-Fraile R, van Gestel TJM, van der Ploeg AT, Pijnappel W.
628 Restoring the regenerative balance in neuromuscular disorders: satellite cell activation as
629 therapeutic target in Pompe disease. *Ann Transl Med*. 2019;7(13):280.
- 630 68. Panelli A, Verfuss MA, Dres M, Brochard L, Schaller SJ. Phrenic nerve stimulation to
631 prevent diaphragmatic dysfunction and ventilator-induced lung injury. *Intensive Care Med*
632 *Exp*. 2023;11(1):94.
- 633 69. Goligher EC, Jonkman AH, Dianti J, Vaporidi K, Beitler JR, Patel BK, et al. Clinical
634 strategies for implementing lung and diaphragm-protective ventilation: avoiding insufficient
635 and excessive effort. *Intensive Care Med*. 2020;46(12):2314-26.

636

637

638

639 **Figure legends.**

640 **Figure 1. RNA sequencing of the diaphragm of mechanically ventilated ICU patients.**

641 **A:** Principal component analysis of sequencing results. Note the clustering of the samples
642 within the CTRL group while this clustering is absent in the ICU groups. This may be due to
643 heterogeneity of patient characteristics within both ICU groups. CTRL $N = 8$; ICU $N = 17$. **B:**
644 Volcano plot and **C:** top 50 DEG heatmap. Top 50 most significantly differentially expressed
645 DEGs for each contrast (sorted by smallest adjusted p -value). 1714 genes were significantly
646 upregulated and 1236 genes were significantly downregulated in the ICU group. Genes with
647 a significance level $p < 0.05$ and a fold change of > 1.5 were deemed differentially expressed.
648 CTRL $N = 8$; ICU $N = 17$. **D:** PANTHER gene set enrichment analysis. Top10 gene sets or
649 pathways enriched for up- or down-regulated genes of one database (dashed line: p -value =
650 0.05). Only shows pathways that are not significant for both directions (up/down) at the same
651 time to identify on/off situations. Significant gene set enrichment is defined by the false
652 discovery rate. CTRL $N = 8$; ICU $N = 17$. **E:** Schematic of the differentially expressed genes
653 that are involved in the intrinsic apoptotic pathway. Genes in green are significantly
654 upregulated and genes in red are significantly downregulated in ICU patients.

655

656 **Figure 2. Caspase-3 mediated apoptosis as a mechanism underlying myonuclear loss**
657 **in the diaphragm of ICU patients.**

658 **A:** Representative images of diaphragm muscle cross-sections stained with TUNEL assay,
659 PCM1 antibody, Dystrophin antibody, and DAPI. Nuclei with a TUNEL-positive signal were
660 designated as apoptotic myonuclei when they were PCM1 positive and were located within
661 the dystrophin barrier. Note the difference in PCM1 immunoreactivity of the TUNEL+ non-
662 myonucleus (left white arrow) and myonucleus (right white arrow). Scale bar top row is 50
663 μm , scale bar bottom row is 20 μm . **B:** Quantification of TUNEL index, calculated as the
664 percentage of TUNEL-positive myonuclei. Total myonuclear count was determined by
665 counting PCM1-positive nuclei. The grey bar represents the mean \pm standard deviation

666 within the groups of patients. Each colored symbol represents the value of a single patient.
667 CTRL $N = 8$; ICU $N = 18$. Significance level was calculated using an unpaired t -test. **C:**
668 Representative images of diaphragm muscle cross-sections stained with Cleaved caspase-3
669 antibody, PCM1 antibody, Laminin antibody and DAPI. Nuclei with a Cleaved Caspase-3
670 positive signal were designated as apoptotic myonuclei when they were PCM1 positive and
671 were located within the laminin barrier. Scale bar top row = $50\mu\text{m}$, scale bar bottom row = 20
672 μm . **D:** Quantification of activated caspase-3 index, calculated as the percentage of activated
673 caspase-3-positive myonuclei. Total myonuclear count was determined by counting PCM1-
674 positive nuclei. The grey bar represents the mean \pm standard deviation within the groups of
675 patients. Each colored symbol represents the value of a single patient. CTRL $N = 7$; ICU $N =$
676 14 . Significance level was calculated using a Mann-Whitney-U test. ICU A+ = ICU group with
677 atrophy, ICU A- = ICU group without atrophy, CTRL = Control group, * = $p < 0.05$, ** = $p < 0.01$

678 **Figure 3. Reduced number of myonuclei in atrophic diaphragm fibers of critically ill**
679 **patients.**

680 **A:** Representative images of single muscle fibers from control (left) and ICU (right) patients.
681 Myofibers are immunofluorescently labeled for lamin A/C (red) and myosin heavy chain
682 (green) Scale bar = $60\mu\text{m}$ **B:** Representative images of 3D rendered single muscle fibers,
683 with segmentation in 3D. Scale bar = $60\mu\text{m}$. **C:** Quantification of myofiber volume, calculated
684 as volume per mm fiber was normalized to a sarcomere length of $2.5\mu\text{m}$. Every grey dot
685 represents the value of a single muscle fiber and the colored symbols represent the mean
686 values of a single patient. Slow-twitch fibers: ICU A+ $N = 14$, $n = 84$; $N = 10$, $n = 50$; CTRL $N =$
687 10 , $n = 48$. Fast-twitch fibers: ICU A+ $N = 14$, $n = 56$; ICU A- $N = 10$, $n = 48$; CTRL $N = 10$,
688 $n = 46$. **D:** Quantification of myonuclear number. Every grey dot represents the value of a
689 single muscle fiber and the colored symbols represent the mean values of a single patient.
690 Black bars indicate the median of the whole group. Slow-twitch fibers: ICU A+ $N = 14$, $n = 84$;
691 ICU A- $N = 10$, $n = 50$; CTRL $N = 10$, $n = 48$. Fast-twitch fibers: ICU A+ $N = 14$, $n = 56$; ICU
692 A- $N = 10$, $n = 48$; CTRL $N = 10$, $n = 46$. **E** Quantification of myonuclear domain size. Every

693 grey dot represents the value of a single muscle fiber and the colored symbols represent the
694 mean values of a single patient. Significance levels were calculated using linear mixed
695 models with the patients as the random factor. Black bars indicate the median of the whole
696 group. Slow-twitch fibers: ICU A $N = 14$, $n = 84$; ICU A- $N = 10$, $n = 50$; CTRL $N = 10$, $n = 48$.
697 Fast-twitch fibers: ICU A+ $N = 14$, $n = 56$; ICU A- $N = 10$, $n = 48$; CTRL $N = 10$, $n = 46$. ICU
698 A+ = ICU group with atrophy; ICU A- = ICU group without atrophy; CTRL = Control group. *
699 denotes $p < 0.05$; ** denotes $p < 0.01$. N = number of patients, n = number of analyzed
700 myofibers.

701

702 **Figure 4. Altered myonuclear morphology in diaphragm myofibers of ICU patients.**

703 **A:** Representative images of unsegmented (left) and segmented (right) 3D-rendered
704 myonuclei within mounted single muscle fibers that were immunofluorescently labeled for
705 lamin A/C. Note the difference in ellipticity and sphericity between the top and the bottom
706 myonucleus. Scale bar = 5 μm **B** Quantification of myonuclear volume. Each grey dot
707 represents the value of a single nucleus. Each colored symbol represents the mean value of
708 a single patient. The black bar represents the mean value within the groups of patients.
709 Significance level was calculated using linear mixed models with the patients as the random
710 factor. CTRL $N = 10$ patients, $n = 6270$ nuclei; ICU A+ $N = 14$ patients; $n = 5463$ nuclei; ICU
711 A- $N = 10$ patients; $n = 6330$ nuclei. **C** Quantification of lamin A/C fluorescence intensity
712 within each nucleus. Each grey dot represents the value of a single nucleus. Each colored
713 symbol represents the mean value of a single patient. The black bar represents the mean
714 value within the groups of patients. Significance level was calculated using linear mixed
715 models with the patients as the random factor. CTRL $N = 10$ patients, $n = 6270$ nuclei; ICU
716 A+ $N = 14$ patients, $n = 5463$; ICU A- $N = 10$ patients, $n = 6330$ nuclei. **D:** Representative
717 images of maximum intensity Z-projections of Z-stacks of myonuclei. Note the difference
718 between the nuclei with a smooth nuclear lamina (left) and a wrinkled nuclear lamina (right).
719 Scale bar = 5 μm . **E:** Quantification of the wrinkling index for each nucleus. Wrinkling index
720 was calculated as the standard deviation of the fluorescence intensity within the segmented

721 nucleus. Each grey dot represents the value of a single nucleus. Each colored symbol
722 represents the mean value of a single patient. The black bar represents the mean value
723 within the groups of patients. Significance level was calculated using linear mixed models
724 with the patients as the random factor. CTRL $N = 10$ patients, $n = 1983$ nuclei; ICU A+ $N =$
725 14 patients, $n = 2601$ nuclei; ICU A- $N = 10$ patients, $n = 2442$ nuclei. ICU A+ = ICU group
726 with atrophy; ICU A- = ICU group without atrophy; CTRL = Control group. * denotes $p <$
727 0.05 ; ** denotes $p < 0.01$.

728

729 **Figure 5. Total transcriptional activity is reduced in atrophic myofibers of ICU patients.**

730 **A:** Schematic of RNA-polymerase-II with phosphorylation at Serine 5 with antibody binding to
731 phosphorylated Serine. This phosphorylation occurs when RNA-Pol-II starts transcribing
732 DNA into mRNA. **B:** Representative images of RNA-Pol-II-Ser5 (magenta), lamin A/C
733 (yellow), and phalloidin (green) labeling of a single Z-plane of a mounted single muscle fiber.
734 Z-stacks were used to create 3D renders of fiber segments and total RNA-Pol-II Ser5
735 fluorescence intensity was measured within each myonucleus, using lamin A/C to segment
736 all nuclei in 3D. Scale bar = $20\ \mu\text{m}$. **C:** Total RNA-Pol-II-Ser5 fluorescence intensity was
737 calculated as the sum of the total RNA-Pol-II-Ser5 fluorescence intensity within each nucleus
738 present within three Z-stacks generated from a single myofiber. CTRL $N = 5$ patients, $n = 48$
739 myofibers; ICU A+ $N = 5$ patients, $n = 48$ myofibers. Each grey symbol represents the value
740 of a single myofiber. Each colored symbol represents the mean value of a single patient. The
741 black bar represents the mean value within the groups of patients. **D:** Total RNA-Pol-II-Ser5
742 fluorescence intensity per segmented nucleus. CTRL $N = 5$ patients, $n = 2817$ nuclei; ICU A+
743 $N = 5$ patients, $n = 2235$ nuclei. Each grey symbol represents the value of a single nucleus.
744 Each colored symbol represents the mean value of a single patient. The black bar represents
745 the mean value within the groups of patients. **E.** Total RNA-Pol-II-Ser5 fluorescence intensity
746 per myofiber volume was calculated as the sum of the total RNA-Pol-II-Ser5 fluorescence
747 intensity within each nucleus present within the myofiber divided by the myofiber volume.

748 CTRL $N = 5$ patients, $n = 48$ myofibers; ICU A+ $N = 5$ patients, $n = 48$ myofibers. Each grey
749 symbol represents the value of a single myofiber. Each colored symbol represents the mean
750 value of a single patient. The black bar represents the mean value within the groups of
751 patients. Significance level was calculated using linear mixed models with the patients as the
752 random factor. ICU A+ = ICU group with atrophy; CTRL = Control group; * denotes $p < 0.05$;
753 ** denotes $p < 0.01$

754

755 **Figure 6. Decreased abundance of PAX7 positive cells in the atrophic diaphragm**

756 **A:** Representative images of diaphragm muscle cross-sections stained with PAX7 antibody,
757 Laminin antibody, and DAPI. Nuclei with a PAX7-positive signal were designated as satellite
758 cells. Scale bar = 50 μm in the top row and 10 μm in the bottom row. **B:** Number of PAX7
759 positive cells present in diaphragm muscle cross sections, normalized for section size. The
760 grey bar represents the median [IQR] within the groups of patients. Each colored symbol
761 represents a single patient. CTRL $N = 6$; ICU $N = 8$. Significance level was calculated using
762 Mann-Whitney U test. **C:** Number of PAX7 positive cells present in diaphragm muscle cross
763 sections, normalized for the number of myofibers. The grey bar represents the median [IQR]
764 within the groups of patients, brackets represent interquartile ranges. Every colored symbol
765 represents a single patient. CTRL $N = 6$; ICU $N = 8$. Significance level was calculated using a
766 Mann-Whitney-U test.

767 ICU = ICU group with atrophy, CTRL = Control group, * = $p < 0.05$, ** = $p < 0.01$

768

769 **Figure 7. Graphical summary**

770 Graphical summary of findings. Created using biorender.com.

771

772

773

774

775 **Table 1. Clinical characteristics of patients.**

Characteristic	Control (n = 10)	ICU Patients (n=24)	ICU A+ (n =14)	ICU A- (n=10)	P-value
Age (years)	67 [60-72]	66 [50-73]	65 [55-71]	60 [49-69]	0.698
Male (%)	7 (70)	15 (63)	7(50)	8 (80)	
BMI (Kg/m ²)	28 [24-32]	25 [21-28]	25 [21-28]	26 [21-28]	0.281
APACHE-3	-	73 [47-111]	78 [53-149]	75[67-89]	0.762
Ventilation (hours)	1.5 [0.9-2.0]	66 [44-193]	63 [45-121] *	90 [18-223] *	<0.001
Controlled ventilation (hours)	2.0 [1-2.3]	64 [32-127] *	64 [34-132]*	55 [16-140]*	<0.001
Myofiber CSA (µm ²)	2469[1708-2973]	1736 [1250-3035]	1341 [1007-1667] *	3159 [2798-4294] *	<0.001
Medical history, n (%)					
Smoking	3 (30)	13 (54)	10(71)	3 (30)	0.072
COPD ≤ G2	3 (30)	3 (13)	2 (14)	1 (10)	0.506
Other lung disease	2 (20)	1 (4)	1 (7)	0 (0)	0.259
Cardiac	1 (10)	3 (13)	2 (14)	1 (10)	0.996
Arterial vascular disease	2 (20)	14 (58)*	12 (86) *	2 (20)	0.010
Hypertension	3 (30)	9 (38)	6 (43)	3 (30)	0.860
CKD	1 (10)	2 (8)	2 (14)	0 (0)	0.535
T2DM	0 (0)	2 (8)	0 (0)	2 (20)	0.179
Hypothyroidism	1 (10)	2 (8)	2 (14)	0 (0)	0.716
Malignancy lung	7 (70)	1 (4) *	0 (0) *	1 (10) *	<0.001
Malignancy other	2 (20)	2 (1)	2 (1)	0 (0)	0.466
Medication					
Steroids	-	18 (75)	11 (79)	9 (90)	0.715
Neuromuscular blockers	-	12 (50)	8 (57)	4 (40)	0.433
Vasopressors	-	19 (79)	10 71)	9 (90)	0.495

776 Data displayed as Median [IQR], p-values calculated with Kruskal-Wallis or chi-squared
777 tests BMI: Body Mass Index, MVhr: duration of mechanical ventilation before biopsy *BMI =*
778 *Body Mass Index* *APACHE = Acute Physiology And Chronic Health Evaluation*, *CSA =*
779 *Cross-Sectional Area*, *COPD = Chronic Obstructive Pulmonary Disease*, *CKD = Chronic*
780 *Kidney Disease*, *T2DM = Type 2 Diabetes Mellitus*, *CID = Chronic Inflammatory Disease*,
781 *P/F-ratio = arterial partial pressure of oxygen (PaO₂) divided by the inspired oxygen*
782 *concentration (FiO₂)*, *A-a gradient = alveolar-arterial gradient*. Data shown as Median [IQR].
783 *P-values of continuous data calculated with one-way analysis of variance or Kruskal-Wallis*
784 *test, depending on distribution of the data. P-values of categorical data calculated with Chi-*
785 *squared test. * indicates a significant difference with the control group calculated with post-*
786 *hoc tests.*

787

788

789 **Table 2. Characteristics of individual patients of quadriceps studies**

Patient	Age (y)	Sex	BMI (kg/m ²)	ICU diagnosis	APACHE-4 score	Duration of MV (h)
1	56-60	M	26	Trauma	139	33.3
2	80-85	M	25	Trauma	94	44.3
5	30-35	F	27	Trauma	76	50.5
6	30-35	M	22	Trauma	76	50.8
8	80-85	M	23	Sepsis	130	28.3
9	60-65	M	25	Trauma	94	17
10	20-25	M	24	Trauma	63	79
11	70-75	M	29	Trauma	40	5
14	70-75	M	28	Resp. failure	97	49
15	66-70	M	20	Resp. failure	104	4
C010	20-25	M	23	-	-	-
C011	20-25	M	22	-	-	-
C-09	56-60	M	26	-	-	-
C-10	50-55	F	23	-	-	-
C-11	56-60	M	32	-	-	-

790

791








Figure 1







Figure 2





Figure 3




Figure 4








Figure 5


A**PAX7****DAPI****Laminin, Merge****B****C****Figure 6**

Graphical summary


Mechanical ventilation in the ICU




Activation of intrinsic apoptotic pathway




Myonuclear apoptosis during atrophy



Loss of myofiber cross-sectional area



Diaphragm weakness and atrophy



Loss of muscle stem cells may further hinder recovery from atrophy




Figure 7